Kawczak P

ORCID: 0000-0003-3902-2744 · 1 paper in corpus

review 2026

Targeting VEGF, PARP, and FRα Pathways in Ovarian Cancer: Clinical Advances with Bevacizumab, Rucaparib, and Mirvetuximab Soravtansine

Journal of clinical medicine ·doi:10.3390/jcm15051742

Ovarian cancer remains a leading cause of gynecologic cancer-related mortality worldwide, and long-term outcomes with conventional cytotoxic chemotherapy remain limited. The integration of targeted therapies has substantially reshaped treat…